Coya Therapeutics (NASDAQ:COYA) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Coya Therapeutics (NASDAQ:COYA) announced its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.14, Zacks reports. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $6.45 on Thursday. The company’s fifty day simple moving average is $6.31 and its two-hundred day simple moving average is $6.48. The firm has a market cap of $107.76 million, a PE ratio of -9.92 and a beta of 0.31. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.42.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, February 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.